← Leaderboards
Rong Yang
Cloudbreak Therapeutics, Llc
$1,377,616
Attributed
$1,377,616
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $700K · FY2020–21$1M$750K$500K$250K$0
'20
'21
Funding mix
By agency
NIH$1,377,616 · 1
By mechanism
R44$1,377,616 · 1
Top collaborators
No co-investigators on record.
Most similar at Cloudbreak Therapeutics, Llc
Same institution · by research overlap
- Jinsong Ni$2,259,579
Others in their field
Other Emerging Leaders on “Affect”
- Chanza Baytop · Westat, Inc.$271,217,917
- Leonard Freedman · Leidos Biomedical Research, Inc.$62,378,387
- Jennifer Marie Suga · Kaiser Foundation Research Institute$29,218,159
- Lynn Briscoe · Leidos Biomedical Research, Inc.$27,788,199
- George Robert Painter · University Of Alabama At Birmingham$27,619,145
- Jessica Brooke Langbaum · Banner Health$22,633,312
Research focus
AffectAnxietyAppearanceBaseBlood VesselsCapsuleChronicClinical ResearchClinical TrialsConjunctivaConjunctival PterygiumCorneaDesignDisease ProgressionDoseDrug VehicleElectroretinographyEmulsionsExcisionEyedropsFda ApprovedFibroblast Growth FactorFormulationAdverse Effects
Grant awards (2)
A Phase 3 Multicenter, Randomized, Vehicle-Controlled Clinical Study to Evaluate the Safety and Efficacy of an Ophthalmic Emulsion of Nintedanib in Pterygium Patients$677,628
R44 · FY2021 · EY · contact PI
A Phase 3 Multicenter, Randomized, Vehicle-Controlled Clinical Study to Evaluate the Safety and Efficacy of an Ophthalmic Emulsion of Nintedanib in Pterygium Patients$699,988
R44 · FY2020 · EY · contact PI